HIGHTIDE-B, also known as Junshengtai Pharmaceuticals-B, submitted the latest monthly securities report to the Hong Kong Exchanges and Clearing Limited on July 31, 2024. The report shows that as of the end of July 2024, the company's statutory/registered share capital remained at US$100,000, with 1,000,000,000 shares and a par value of US$0.0001 per share. There have been no increases or decreases in the number of shares. At the same time, the number of issued shares (excluding treasury shares) remains at 514,770,668 shares, and there have been no changes this month. The report does not mention changes in share options, warrants, convertible bonds, other agreements or arrangements, and treasury shares. The company confirms that all securities issuances or sales or transfers of treasury shares have been authorized by the Board of Directors and comply with relevant listing rules and legal requirements. The report was submitted by Executive Director and CEO, Dr. Liu Liping, on August 5, 2024.

HIGHTIDE-B, also known as Junshengtai Pharmaceuticals-B, submitted the latest monthly securities report to the Hong Kong Exchanges and Clearing Limited on July 31, 2024. The report shows that as of the end of July 2024, the company's statutory/registered share capital remained at US$100,000, with 1,000,000,000 shares and a par value of US$0.0001 per share. There have been no increases or decreases in the number of shares. At the same time, the number of issued shares (excluding treasury shares) remains at 514,770,668 shares, and there have been no changes this month. The report does not mention changes in share options, warrants, convertible bonds, other agreements or arrangements, and treasury shares. The company confirms that all securities issuances or sales or transfers of treasury shares have been authorized by the Board of Directors and comply with relevant listing rules and legal requirements. The report was submitted by Executive Director and CEO, Dr. Liu Liping, on August 5, 2024.